Rapamycin slows IgA nephropathy progression in the rat

American Journal of Nephrology

Volumn 39, Issue 3, 2014, Pages 218-229

  Tian, Jihua ^a   Wang, Yanhong ^a   Zhou, Xiaoshuang ^a   Li, Yanjiao ^a   Wang, Chen ^a   Li, Jiaming ^a   Li, Rongshan ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

IgA nephropathy; Mammalian target of rapamycin; mTOR; Rapamycin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; BRILLIANT BLUE; BROXURIDINE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; HEMOGLOBIN; NITROGEN; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; S6 KINASE; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UREA; CREATININE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, RAT; TARGET OF RAPAMYCIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOANALYZER; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DOWN REGULATION; DRUG MECHANISM; END STAGE RENAL DISEASE; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GLOMERULAR STRUCTURE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY CELL; KIDNEY CORTEX; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; THROMBOCYTOPENIA; WESTERN BLOTTING; ENZYME ACTIVATION; GLOMERULUS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GLOMERULONEPHRITIS, IGA; KIDNEY; LIVER; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROSIS; GLOMERULONEPHRITIS, IGA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY GLOMERULUS; LIVER; MALE; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84895671562     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000358844     Document Type: Article

References (39)

1. Donadio JV, Grande JP: IgA nephropathy. N Engl J Med 2002; 347: 738-748.
2. Floege J, Feehally J: IgA nephropathy: recent developments. J Am Soc Nephrol 2000; 11: 2395-2403.
3. Praga M, et al: Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583.
4. Floege J, Eitner F: Combined immunosuppression in high-risk patients with IgA nephropathy? J Am Soc Nephrol 2010; 21: 1604-1606.
5. Coppo R, Pozzi C, Amore A: The role of steroids in the treatment of IgA nephropathy (in Italian). G Ital Nefrol 2009; 26: 421-441.
6. Buemi M, et al: Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 2000; 67: 427-431.
7. Hogg RJ, et al: Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1: 467-474.
8. Lai KN: Pathogenesis of IgA nephropathy. Nat Rev Nephrol 2012; 8: 275-283.
9. Brunskill NJ: Rapamycin: a new string to the antiproteinuric bow? J Am Soc Nephrol 2005; 16: 1878-1879.
10. Liu Y: Rapamycin and chronic kidney disease: beyond the inhibition of inflammation. Kidney Int 2006; 69: 1925-1927.
11. Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005; 17: 596-603.
12. Lloberas N, et al: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17: 1395-1404.
13. Tao Y, et al: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16: 46-51.
14. Bonegio RG, et al: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16: 2063-2072.
15. Chen JK, et al: Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 2005; 16: 1384-1391.
16. Hochegger K, et al: Differential effects of rapamycin in anti-GBM glomerulonephritis. J Am Soc Nephrol 2008; 19: 1520-1529.
17. Lock HR, Sacks SH, Robson MG: Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production. Am J Physiol Renal Physiol 2007; 292:F76-F81.
18. Kramer S, et al: Low-dose mTOR inhibition by rapamycin attenuates progression in antithy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol 2008; 294: F440-F449.
19. Cruzado JM, et al: Low-dose sirolimus combined with angiotensin- converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy. Nephrol Dial Transplant 2011; 26: 3596-3602.
20. Lai KN, et al: Additive effect of PPAR-α agonist and ARB in treatment of experimental IgA nephropathy. Pediatr Nephrol 2011; 26: 257-266.
21. Katzir Z, et al: Effect of atorvastatin on IgA nephropathy in the rat. Clin Nephrol 2013; 79: 214-220.
22. Huang H, et al: Tonsillar CD4+CD25+ regulatory T cells from IgA nephropathy patients have decreased immunosuppressive activity in experimental IgA nephropathy rats. Am J Nephrol 2013; 37: 472-480.
23. Zhong Q, et al: The study of Chinese medicinal herbal formula Shen San Fang in the treatment of experimental IgA nephropathy. Am J Chin Med 2005; 33: 613-626.
24. 1in IgA nephropathy in the rat. Mol Genet Metab 1998; 63: 224-229.
25. Trachtman H, et al: Vitamin E ameliorates renal injury in an experimental model of immunoglobulin A nephropathy. Pediatr Res 1996; 40: 620-626.
26. Liboska R, et al: Most anti-BrdU antibodies react with 2′-deoxy-5-ethynyluridine -the method for the effective suppression of this cross-reactivity. PLoS One 2012; 7:e51679.
27. Segarra A: Progress in understanding the pathogenesis of IgA nephropathy: new perspectives for the near future? Nefrologia 2010; 30: 501-507.
28. Stoycheff N, et al: Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrol Dial Transplant 2011; 26: 848-857.
29. Diekmann F, et al: Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 2007; 18: 2653-2660.
30. Schlondorff D, Banas B: The mesangial cell revisited: no cell is an island. J Am Soc Nephrol 2009; 20: 1179-1187.
31. Makino H: Glomerular extracellular matrix in glomerulosclerosis by molecular biology. Nihon Rinsho 1992; 50: 3038-3045.
32. Imai E, et al: Introduction of a foreign gene into the kidney in vivo: development of glomerulosclerosis by the transfection of genes for PDGF and TGF-β. Contrib Nephrol. Basel, Karger, 1994, vol 107, pp 205-215.
33. Mima A, et al: Activation of Src mediates PDGF-induced Smad1 phosphorylation and contributes to the progression of glomerulosclerosis in glomerulonephritis. PLoS One 2011; 6: e17929.
34. 1and apoptosis in the progression of glomerulosclerosis in human IgA nephropathy. Clin Nephrol 2006; 65: 385-392.
35. Groth CG, et al: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042.
36. Brattstrom C, et al: Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65: 1272-1274.
37. Kahan BD, Napoli KL: Role of therapeutic drug monitoring of rapamycin. Transplant Proc 1998; 30: 2189-2191.
38. Inoki K, et al: mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011; 121: 2181-2196.
39. Tumlin JA, et al: A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006; 1: 109-116.